NTLA Jul 2024 40.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 10:51AM EDT. Market open.
| Previous Close | 0.3500 |
| Open | 0.3000 |
| Bid | 0.0500 |
| Ask | 0.3500 |
| Strike | 40.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.3000 - 0.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 289 |
GlobeNewswireIntellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across a
ZacksIntellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Simply Wall St.Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) just released its quarterly report and things are looking bullish. Results...
© 2024 Yahoo. All rights reserved.